Immunotherapy represents a major therapeutic breakthrough in cancer treatment and the discovery of immune checkpoint molecules such as PD-1/PDL-1 and CTLA-4 has led to major changes to the therapeutic landscape of cancer immunotherapy. Immune checkpoint inhibitors (ICIs) take advantage of immune system components to boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes. ICIs alone or in combination with conventional treatments, such as radiotherapy and chemotherapy, have achieved considerable success as standard therapy in cancers. However, there remain unresolved clinical issues following by ICIs therapy, such as treatment resistance and adverse events, as well as whether there exist novel ICIs other than PD1/PDL-1/CTLA-4 that have promising cancer therapeutic potential. Therefore, we propose this Research Topic to collect the latest progress of ICIs for cancer therapy and provide a platform to discuss unresolved clinical issues encountered by physicians and scientists.
We welcome compelling studies covering but not limited to the following:
1) Clinical or translational research on novel and effective regimes with ICIs alone or in combination with other therapies, such as chemotherapy, radiotherapy, etc.
2) Clinical or translational research on novel ICIs (other than PD1/PDL-1/CTLA-4) for cancer therapy.
3) Novel strategies for the management of adverse events related to ICIs.
4) Underlying mechanisms of ICIs treatment resistance.
5) Molecular markers for clinical evaluation of ICIs therapeutic effect.
Please note: manuscripts consisting solely of bioinformation or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic editor Dr. Huafeng Wei is employed by Innovent Cells Pharmaceutical (Suzhou) Co., Ltd (and declares no competing interests with regards to the Research Topic Subject). All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Immunotherapy represents a major therapeutic breakthrough in cancer treatment and the discovery of immune checkpoint molecules such as PD-1/PDL-1 and CTLA-4 has led to major changes to the therapeutic landscape of cancer immunotherapy. Immune checkpoint inhibitors (ICIs) take advantage of immune system components to boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes. ICIs alone or in combination with conventional treatments, such as radiotherapy and chemotherapy, have achieved considerable success as standard therapy in cancers. However, there remain unresolved clinical issues following by ICIs therapy, such as treatment resistance and adverse events, as well as whether there exist novel ICIs other than PD1/PDL-1/CTLA-4 that have promising cancer therapeutic potential. Therefore, we propose this Research Topic to collect the latest progress of ICIs for cancer therapy and provide a platform to discuss unresolved clinical issues encountered by physicians and scientists.
We welcome compelling studies covering but not limited to the following:
1) Clinical or translational research on novel and effective regimes with ICIs alone or in combination with other therapies, such as chemotherapy, radiotherapy, etc.
2) Clinical or translational research on novel ICIs (other than PD1/PDL-1/CTLA-4) for cancer therapy.
3) Novel strategies for the management of adverse events related to ICIs.
4) Underlying mechanisms of ICIs treatment resistance.
5) Molecular markers for clinical evaluation of ICIs therapeutic effect.
Please note: manuscripts consisting solely of bioinformation or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic editor Dr. Huafeng Wei is employed by Innovent Cells Pharmaceutical (Suzhou) Co., Ltd (and declares no competing interests with regards to the Research Topic Subject). All other Topic Editors declare no competing interests with regards to the Research Topic subject.
